Related Experiment Video
Updated: Aug 8, 2026

Creating Dynamic Images of Short-lived Dopamine Fluctuations with lp-ntPET: Dopamine Movies of Cigarette Smoking
Published on: August 6, 2013
Behavioral tobacco cessation treatments: yesterday's news or tomorrow's headlines?
1H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL 33617, USA. brandont@moffitt.usf.edu
Abstract:
This article reviews behavioral treatments (broadly defined) for tobacco use, discusses cessation treatments for cancer patients, and predicts the future direction of behavioral interventions. During the past decade, progress in behavioral treatments for tobacco use has not kept pace with progress made in the development of pharmacotherapies. Nevertheless, the efficacy and cost-effectiveness of behavioral treatments compare favorably with the pharmacotherapies. Intensive behavioral interventions with empirical support are reviewed, and the difficulty of attracting smokers to intensive smoking clinics is discussed. Because there has been little research on tobacco cessation interventions designed specifically for cancer patients, clinicians should follow the Five A's suggested in the recent Clinical Practice Guidelines: Ask, Advise, Assess, Assist, and Arrange. The future of behavioral treatments will likely emphasize both minimal interventions (via telephone, Internet, and written materials) designed for broad impact and intensive interventions targeted to particular subgroups of smokers with the need and motivation for them (eg, the heavily nicotine-dependent, pregnant women, depression-prone smokers, and medical patients). A blurring of the distinctions between behavioral interventions, pharmacotherapies, and community-oriented approaches is also likely as multidimensional cessation strategies are developed.
More Related Videos
06:39Electroencephalographic, Heart Rate, and Galvanic Skin Response Assessment for an Advertising Perception Study: Application to Antismoking Public Service Announcements
Published on: August 28, 2017
09:29Investigating Drivers of Antireward in Addiction Behavior with Anatomically Specific Single-Cell Gene Expression Methods
Published on: August 4, 2022
Related Concept Videos
Drug Dependence
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
CNS Depressants: Alcohol and Nicotine
Classical Conditioning in Daily Life
John B. Watson and Rosalie Rayner famously demonstrated the development of fear through classical conditioning in their experiment with Little Albert. They paired the...
Timing and Consequences on Behavior
Humans, however, can respond to delayed reinforcers. We often make decisions between immediate small rewards and delayed larger rewards. This ability to delay gratification is a significant factor...
Behavior Therapy
Exposure therapy is a cornerstone of behavioral treatment for anxiety disorders. It involves systematic exposure to feared stimuli, either in real...